The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1231
Clobetasol Propionate (Clobex) Spray for Psoriasis
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved a new spray formulation of the super-high-potency corticosteroid clobetasol propionate 0.05% (Clobex – Galderma) for treatment of moderate to severe plaque psoriasis in adults. Clobetasol propionate is also available as a cream, ointment, gel, solution, foam, lotion and shampoo.

TOPICAL CORTICOSTEROIDS FOR PSORIASIS — Topical corticosteroids are the most widely used drugs for treatment of psoriasis.1 For many years, pharmaceutical manufacturers have used the ability of topical corticosteroids to induce vasoconstriction in normal human skin as a measure of their clinical potency. Vasoconstrictor assays generally correlate with antiinflammatory activity. Topical corticosteroids vary in potency from the super-high-potency drugs listed in the table to the least potent 0.5% hydrocortisone.

VEHICLES — Ointments are generally considered the ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Clobetasol Propionate (Clobex) Spray for Psoriasis
Article code: 1231b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian